HeartFlow Stock
Cardiovascular application software
About HeartFlow Stock
HeartFlow is a medical technology company that provides new methods of diagnosis and treatment of cardiovascular disease. It offers HeartFlow Analysis, a non-invasive solution available in the United States, Europe, and Japan that helps a physician evaluate whether a patient has significant coronary artery disease based on anatomy and physiology. Christopher K. Zarins and Charles Anthony Taylor founded Cardiovascular Simulation in 2007 that became HeartFlow in May 2009. Its headquarters is in Redwood City in California.
Investors
Baillie Gifford
Spotify, AUTO1 Group, Ginkgo Bioworks, Carbon, Indigo AG, HeartFlow, Tempus, Thumbtack, HelloFresh, Anaplan
LifeForce Capital
Martis Capital
Wellington Management
Funding History
| July 2009 | $2.0M |
|---|---|
| August 2010 | $6.9M |
| August 2010 | $10.1M |
| December 2011 | $105M |
| January 2015 | $111M |
| November 2017 | $340M |
Management
Chief Executive Officer & President
Dana Mead
Chief Medical Officer
Campbell Rogers
Chief Technology Officer
Charles Taylor
Chief Commercial Officer
Lance Scott
Chief Ethics & Compliance Officer & General Counsel
Noemi Espinosa
Chief Information Security Officer
Auston Davis
Chief People Officer
Renata Naoumov
Press
BioWorld - Jan, 31 2020
businesswire - Sep, 12 2019
bioportfolio - May, 23 2019
computerworlduk - Feb, 21 2019
massdevice - Feb, 8 2019
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from HeartFlow or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
